Vivo Capital, LLC Q4 2016 Filing
Filed February 14, 2017
Portfolio Value
$300.4B
Holdings
24
Report Date
Q4 2016
Filing Type
13F-HR
All Holdings (24 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACRSAclaris therapeutics | 3,283,569 | $89.1B | 29.66% | |
| 2 | ASNDAscendis Pharma | 1,766,832 | $35.8B | 11.90% | |
| 3 | CDXSCodexis, Inc. | 5,294,825 | $24.4B | 8.11% | |
| 4 | —Nabriva Therapeutics AG | 4,021,559 | $24.0B | 7.98% | |
| 5 | CLDNEUREiger BioPharmaceuticals | 1,787,091 | $20.8B | 6.93% | |
| 6 | —Aimmune Therapeutics, Inc. | 763,009 | $15.6B | 5.19% | |
| 7 | —Advanced Accelerator Applications S.A. | 455,798 | $12.2B | 4.06% | |
| 8 | —Trevena, Inc. | 1,728,000 | $10.2B | 3.38% | |
| 9 | —Foamix Pharmaceuticals Ltd. | 855,000 | $9.5B | 3.16% | |
| 10 | RGNXRegenxbio Inc. | 502,863 | $9.3B | 3.10% | |
| 11 | —Agile Therapeutics, Inc. | 1,513,975 | $8.6B | 2.87% | |
| 12 | —CoLucid Pharmaceuticals, Inc. | 225,000 | $8.2B | 2.73% | |
| 13 | —Strongbridge Biopharma plc | 3,000,000 | $7.2B | 2.40% | |
| 14 | —Capnia, Inc. | 7,456,984 | $6.0B | 2.01% | |
| 15 | —BioPharmX Corporation | 12,814,286 | $4.8B | 1.60% | |
| 16 | —Akari Therapeutics Plc | 527,842 | $3.7B | 1.24% | |
| 17 | —ProNAi Therapeutics, Inc. | 2,438,270 | $3.6B | 1.21% | |
| 18 | KALVKalVista Pharmaceuticals, Inc. | 300,325 | $2.1B | 0.71% | |
| 19 | —Sunesis Pharmaceuticals, Inc. | 500,000 | $1.8B | 0.60% | |
| 20 | RVNCEURReVance Therapeutics, Inc. | 77,373 | $1.6B | 0.53% | |
| 21 | DVAXDynavax Technologies Corporation | 359,828 | $1.4B | 0.47% | |
| 22 | —Ocera Therapeutics, Inc. | 153,331 | $322.0M | 0.11% | |
| 23 | —Zosano Pharma Corp | 98,515 | $77.0M | 0.03% | |
| 24 | —Capnia, Inc. | 943,858 | $76.0M | 0.03% |